In a patient taking duloxetine 90 mg who continues to experience mood instability, what augmentation medications are appropriate to address breakthrough symptoms?

Augmentation Strategy for Duloxetine 90mg with Persistent Mood Symptoms

Add bupropion sustained-release (up to 400 mg/day) as your first-line augmentation strategy for breakthrough mood symptoms on duloxetine 90mg. This combination has the strongest evidence base and offers superior tolerability compared to other augmentation options 1, 2.

Evidence-Based Augmentation Approach

First-Line Augmentation: Bupropion SR

The STAR*D trial—the largest and highest-quality study of treatment-resistant depression—demonstrated that bupropion SR augmentation produces equivalent remission rates to buspirone (approximately 30% remission) but with significantly better tolerability 1, 2. Key advantages include:

• Lower discontinuation rates due to adverse events (12.5% vs 20.6% for buspirone, P<0.009) 2
• Greater symptom reduction (25.3% vs 17.1% improvement in depression scores, P<0.04) 2
• Complementary mechanism: Bupropion's dopaminergic/noradrenergic activity complements duloxetine's serotonin-norepinephrine reuptake inhibition 3

A retrospective study specifically examining duloxetine-bupropion combination showed 60% response rates with 30% achieving full remission, with the combination generally well-tolerated at mean doses of duloxetine 60mg + bupropion 175mg 3.

Alternative Augmentation Options

If bupropion is contraindicated or ineffective:

Second-line: Aripiprazole or other atypical antipsychotics 1, 4

• One trial showed aripiprazole superior to bupropion augmentation (55.4% vs 34% remission)
• All 10 major depression guidelines recommend atypical antipsychotics as augmentation 4
• Monitor for metabolic side effects, akathisia, and weight gain

Third-line: Lithium augmentation 1, 5, 4

• Historically the most studied augmentation strategy with consistent evidence
• Particularly effective when added to tricyclics, but also effective with SNRIs
• Requires therapeutic drug monitoring, renal/thyroid monitoring
• All major guidelines recommend lithium as an option 4

Fourth-line: Buspirone (up to 60 mg/day) 1, 2

• STAR*D showed equivalent efficacy to bupropion but worse tolerability
• Higher discontinuation rates due to side effects
• May be useful if patient has comorbid anxiety

Critical Safety Considerations

Drug Interactions with Duloxetine

Avoid or use extreme caution with 6:

• MAOIs: Absolute contraindication (risk of serotonin syndrome)
• Thioridazine: Contraindicated due to cardiac arrhythmia risk
• Potent CYP1A2 inhibitors (ciprofloxacin, fluvoxamine): Avoid combination
• Heavy alcohol use: Associated with severe liver injury

Serotonin Syndrome Risk

When adding any augmentation agent, monitor for serotonin syndrome symptoms 6:

• Agitation, confusion, hallucinations
• Tachycardia, blood pressure changes
• Hyperthermia, diaphoresis
• Muscle rigidity, tremor, hyperreflexia
• Nausea, vomiting, diarrhea

This risk is particularly elevated when combining duloxetine with other serotonergic agents (triptans, tramadol, fentanyl, lithium) 6.

Bleeding Risk

Duloxetine increases bleeding risk, which is further amplified by NSAIDs, aspirin, or anticoagulants 6. Counsel patients about this risk before adding augmentation therapy.

Practical Implementation

Starting bupropion SR augmentation:

1. Begin with 150 mg once daily for 3-4 days
2. Increase to 150 mg twice daily (300 mg/day)
3. Can titrate to maximum 400 mg/day if needed
4. Assess response after 4-8 weeks 2

Monitor for:

• Increased anxiety/agitation (reported in 2/10 patients in duloxetine-bupropion combination) 3
• Blood pressure elevation (duloxetine already increases BP; monitor closely) 6
• Seizure risk (bupropion lowers seizure threshold; avoid if seizure history)
• Insomnia (dose bupropion earlier in day if occurs)

When Augmentation Fails

The 2023 American College of Physicians guideline found no significant differences between switching antidepressants versus augmentation strategies 1. If augmentation with bupropion fails after adequate trial (8-12 weeks), consider:

• Switching to a different antidepressant class entirely
• Trying alternative augmentation (aripiprazole, lithium)
• For severe treatment-resistant cases: ketamine/esketamine (requires multiple failed trials first) 7

Common Pitfalls to Avoid

1. Don't add multiple augmenters simultaneously—this makes it impossible to determine what's working and increases side effect burden
2. Don't underdose the augmenter—bupropion needs 300-400mg/day for optimal effect 2
3. Don't assess response too early—allow 4-8 weeks before declaring failure
4. Don't forget to optimize duloxetine first—ensure patient is actually taking 90mg consistently and has adequate blood levels (therapeutic range 20-120 ng/mL) 8